Presentation Slides - February 26, 2015
Stop TB Meeting
Update on global TB epidemiology
(for presentation slides, please email ferguson-king@bclung.ca)
Dr. Mario Raviglione, World Health Organization, Geneva, Switzerland
Global MDR-TB Update
Dr. Paul Nunn, London, UK
MDR-TB: Linking Diagnosis and Treatment
Dr. Charles Daley, National Jewish Medical and Research Center, Denver, CO, USA
Programmatic technical assistance in high burden DR - TB settings
Dr. Lisa Chen, Curry International TB Center, San Francisco, CA, USA
Shortened MDR - TB Regimen
Dr. ID Rusen, The Union, Paris, France (IUATLD)
Multidrug-resistent TB among immigrants and refugees to the US
Dr. Sasi Jonnalagadda, Centers for Diease Control and Prevention, Atlanta, GA, USA
Nursing-Sponsored Session
Role of social determinants of health on TB among Inuit in Canada
Ms. Anna Claire Ryan, Inuit Tapiriit Kanatami, Ottawa, ON, Canada
TAIMA TB - Community-driven studies for TB prevention and control in Nunavut
(for presentation slides, please email ferguson-king@bclung.ca)
Dr. Gonzalo Alvarez, University of Ottawa, ON, Canada
Tipping points in the TB experience of Aboriginal Peoples of the Canadian Prairies
Dr. Maria Maya, University of Alberta, Edmonton, AB, Canada
TB program and smoking cessation campaign
Dr. Amy Sullivan, Multnomah County Health Department, Portland, OR, USA
Housing-related determinants of TB infection and disease in Nunavik, Quebec
Dr. Faiz Ahmad Khan, McGill International TB Centre, Montreal QC, Canada
Keynote Speakers
The Beyond TB Lecture: Migrants in need: Evolving patterns, ongoing challenges
Prof. Catherine Dauvergne, University of British Columbia Law, Vancouver, BC, Canada
The George Comstock Lecture: Why can't we eliminate tuberculosis?
Dr. Neil Schluger, Columbia University Medical Center, New York, NY, USA
Presentation Slides - February 27, 2015
Re-Examining TB Control Policies and Controversies
Health care worker screening for LTBI in North America
Dr. Susan Dorman, Johns Hopkins University, Baltimore, MD, USA
Value of TB screening among foreign born persons
Dr. Pennan Barry, USA California Department of Public Health, Richmond, CA, USA
Isolation and quarantine: Evolving evidence and practice - US public health perspective
Dr. Gisela Schecter, UCSF and California Department of Public Health, Richmond, CA, USA
Developing a surveillance definition for binational TB cases
Ms. Rachel Yelk-Woodruff, Centers for Disease Control and Prevention, Atlanta, GA, USA
TB in Special Populations
The Public Health impact of TB in the correctional system
Ms. Sarah Bur, Federal Bureau of Prisons, Washington, DC, USA
Women and TB: Impact of gender
Dr. Jane Carter, Brown University, Providence, RI, USA
Challenges in management: Solid organ transplantation and TB
Dr. Michele I. Morris, University of Miami Miller School of Medicine, Miami, FL, USA
Risk of adverse infant outcomes associated with maternal TB in a low burden setting
Dr. Sylvia LaCourse, University of Washington, Seattle, WA, USA
Presentation Slides - February 28, 2015
TB and Diabetes
Roadblocks on the path to TB and DM implementation in New Mexico
Ms. Diana Fortune, New Mexico Department of Health, Santa Fe, NM, USA
Implementing TB-DM for your TB program
(for presentation slides, please email ferguson-king@bclung.ca)
Dr. Richard Brostrom, Department of Health, Honolulu, HI, USA
Refugees with Diabetes Mellitus have higher prevalence of latent TB infection
Dr. Matthew Magee, Georgia State University School of Public Health, Atlanta, GA, USA
TB Pharmacology
Therapeutic drug monitering for TB
Dr. Scott Heysell, University of Virginia School of Medicine, Charlottesville, VA, USA
Therapeutic drug monitering for improving TB treatment outcomes
Dr. Randall Reves, Denver Department of Health, Denver, CO, USA
Pharmacokinetics and doses of anti-TB drugs in children
Prof. Simon Schaaf, Stellenbosch University, Faculty of Medicine, Cape Town, SA
Clinical trials: Optimal use of new and existing medications
Dr. William J. Burman, Denver Health Hospital, Denver, CO, USA
DM2 is associatied with severe adverse effects in drug resistent TB
Dr. Marcela Veronica Muñoz-Torrico, National Institute of Respiratory Diseases, Mexico City, Distrito Federal, Mexico